Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 13/20 | 0.36 |
| ▸ | TP53 | P04637 | 8/20 | 0.36 |
| ▸ | MDM4 | O15151 | 2/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | QPCT | Q16769 | 1/20 | 0.33 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.33 |
| ▸ | ACP1 | P24666 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25005507 | 0.97 | MDM2 (0.38) | MDM2TP53MDM4PPARDMTOR | |
| SCHEMBL30224518 | 0.84 | MTOR (0.36) | MDM2TP53MDM4PPARDMTOR | |
| SCHEMBL30224347 | 0.84 | MDM2 (0.34) | MDM2PPARDMTORQPCTQPCTL | |
| SCHEMBL25004957 | 0.84 | MTOR (0.36) | MDM2TP53MDM4PPARDMTOR | |
| SCHEMBL23991683 | 0.84 | MDM2 (0.34) | MDM2PPARDMTORQPCTQPCTL | |
| SCHEMBL25005978 | 0.84 | MTOR (0.36) | MDM2TP53MDM4PPARDMTOR | |
| SCHEMBL30224149 | 0.83 | PLAU (0.38) | MTORSYK | |
| SCHEMBL23992929 | 0.83 | PLAU (0.38) | MTORSYK | |
| SCHEMBL25005578 | 0.83 | MTOR (0.35) | MDM2TP53MDM4PPARDMTOR | |
| SCHEMBL30224496 | 0.83 | MTOR (0.35) | MDM2TP53MDM4PPARDMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143194-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | MDM2 2083/4885TP53 85/4885MDM4 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.